In this review:
Tazemetostat in R/R follicular lymphoma
CLL1-CD33 compound CAR-T cells in AML
Busulphan + melphalan in multiple myeloma
Survival predictors in myelofibrosis treated with JAK1/2 inhibitor
Quizartinib in FLT3-ITD mutated R/R AML
Vitamin D deficiency reduces survival in Hodgkin lymphoma
Standard vs low dose rituximab in primary ITP
Role of MRD in AML in CR2 after alloSCT
ASCT in older myeloma patients
ASCT in AL amyloidosis
Second-line splenectomy vs rituximab in R/R ITP
Please login below to download this issue (PDF)